North America Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report

Market Outlook

The North America liquid biopsy market, valued at USD 4.5 billion in 2025, is projected to reach USD 5.2 billion in 2026 and USD 17.4 billion by 2035, representing a CAGR of 14.4% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of technology, next-generation sequencing currently dominates (nearly 50%) the current market.
• With respect to type of sample, blood sub-segment holds the highest market share of the current market.
• Based on type of circulating biomarker, circulating tumor DNA holds the largest share of the current market.
• In terms of the type of cancer, breast cancer currently dominates (about 30%) the current market.
• With respect to application area, early diagnosis holds the highest share of the current market.
• Based on end-user, hospitals / laboratories sub-segment currently dominates the market.

Key Market Statistics

• Market Size in 2026: $ 5.2 Billion
• Estimated Market Size in 2035: $ 17.4 Billion
• CAGR (2026-2035): 14.4%

Market Introduction

Tissue biopsy has historically served as the standard approach for cancer diagnosis and molecular profiling, as it allows clinicians to directly examine tumor tissue and identify disease-specific characteristics. However, its invasive nature often creates challenges for patients, including pain, discomfort, procedural risk, and limited feasibility for repeated testing. These limitations become particularly important in oncology, where continuous monitoring is required to understand disease progression, treatment response, and the emergence of resistance. As a result, the industry has increasingly shifted its focus toward less invasive diagnostic approaches that can provide timely and clinically meaningful insights with lower patient burden.

Liquid biopsy has emerged as one of the most promising solutions to address this unmet need. By analyzing blood, plasma, urine, or other bodily fluids, liquid biopsy tests can detect circulating biomarkers such as circulating tumor DNA, cell-free DNA, circulating tumor cells, and extracellular vesicles. Since these tests are minimally invasive and can be repeated over time, they are increasingly being used to support early cancer detection, therapy selection, treatment monitoring, minimal residual disease assessment, and recurrence tracking. The National Cancer Institute has also highlighted that ctDNA-based liquid biopsies may be useful for monitoring treatment response because they are non-invasive and suitable for frequent repetition.

In North America, the adoption of liquid biopsy is gaining strong momentum, supported by the region's high cancer burden, advanced oncology infrastructure, strong reimbursement environment, and growing focus on precision medicine. Notably, in the US alone, around 2.11 million new cancer cases and 626,140 cancer deaths are projected in 2026, underscoring the need for scalable, accessible, and patient-friendly diagnostic solutions.

The region has also witnessed important regulatory milestones, including the FDA approval of Guardant360 CDx for comprehensive tumor mutation profiling across solid tumors and FoundationOne Liquid CDx as a liquid biopsy next-generation sequencing-based companion diagnostic. These approvals have strengthened clinical confidence in blood-based genomic profiling and have helped position liquid biopsy as an important tool in North America's oncology precision medicine ecosystem.

Leading Companies and Their Market Relevance in the North America Liquid Biopsy Market

Market Segmentation

Based on our market research, we have segmented the North America liquid biopsy market forecast into type of technology, type of sample, type of circulating biomarker, type of cancer, application area and end-user.

By Type of Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction

By Type of Sample

• Blood
• Other Samples

By Type of Circulating Biomarker

• Circulating Tumor DNA
• Cell Free DNA
• Cell Free RNA
• Exosomes
• Other Circulating Biomarkers

By Type of Cancer

• Breast Cancer
• Colorectal Cancer
• Prostate cancer
• Lung Cancer
• Bladder Cancer
• Melanoma
• Thyroid Cancer
• Gastric Cancer
• Head and Neck Cancer
• Leukemia
• Brain Cancer
• Liver Cancer
• Cervical Cancer
• Ovarian Cancer
• Oesophagus Cancer
• Pancreatic Cancer
• Nasopharyngeal cancer
• Sarcoma

By Application Area

• Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

By End-user

• Hospitals / Laboratories
• Research Institutes
• Other End-users

North America Liquid Biopsy Market Key Insights

What are the Key Drivers for North America Liquid Biopsy Market Growth?

• Growing Preference for Minimally Invasive Cancer Testing: Traditional tissue biopsy remains important, but it is invasive, painful for some patients, and not always feasible for repeated testing. Liquid biopsy offers a more patient-friendly alternative by using blood or other bodily fluids to detect circulating tumor DNA, cell-free DNA, circulating tumor cells, and other biomarkers. This makes it especially valuable for patients with advanced cancers, hard-to-access tumors, or cases where repeated disease monitoring is required.
• Rising Adoption of Precision Oncology: The growth of precision medicine is directly supporting the North America liquid biopsy market. Oncologists increasingly require molecular profiling to identify actionable mutations, select targeted therapies, and monitor resistance mechanisms. Liquid biopsy supports this need by enabling blood-based genomic profiling when tissue is insufficient, unavailable, or difficult to obtain.

What are the Main Challenges for Market Growth?

• Limited Sensitivity in Early-Stage Cancer Detection: One of the major challenges for liquid biopsy is detecting cancer at very early stages, when the amount of circulating tumor DNA or other tumor-derived biomarkers in blood can be extremely low. This can increase the risk of false-negative results, especially in low-tumor-burden cancers or tumors that shed limited DNA into circulation. As a result, while liquid biopsy is gaining strong traction in advanced cancer profiling and monitoring, broader adoption in early cancer screening still requires further improvement in assay sensitivity and clinical validation.
• Risk of False Positives Due to Biological Noise: Liquid biopsy results can sometimes be affected by non-tumor-related genetic alterations, particularly clonal hematopoiesis, where age-related mutations in blood cells may appear in cell-free DNA analysis. This creates interpretation challenges because some detected mutations may not originate from the tumor itself. In North America, where liquid biopsy is increasingly being used for precision oncology and screening, reducing false positives is critical to avoid unnecessary follow-up procedures, patient anxiety, and inappropriate treatment decisions.

Recent Developments in North America Liquid Biopsy Market

• In July 2026, Caris Life Sciences commercially launched Caris Detect™, a multi-cancer early detection blood test in the US. The test uses ultra-deep whole-genome sequencing, whole-transcriptome sequencing and AI algorithms to detect cancer-associated molecular signals, supporting the expansion of liquid biopsy beyond advanced cancer profiling into early detection.
• In July 2026, UnitedHealth Group began covering Guardant Health's Shield™ blood test for colorectal cancer screening under its reimbursement policy. The coverage enables eligible members aged 45 years or older to access the FDA-approved blood-based screening test with reduced financial barriers, increasing total covered lives in the US to more than 100 million and supporting broader adoption of non-invasive colorectal cancer screening.
• In June 2026, Quest Diagnostics received New York State Department of Health CLEP approval for Haystack MRD®, its ctDNA-based liquid biopsy test for minimal residual disease detection in solid tumors. With this approval, Haystack MRD became authorized for patient testing across all 50 US states, broadening access to MRD testing for recurrence detection and treatment monitoring.
• In June 2026, Foundation Medicine received FDA approval for FoundationOne®Liquid CDx as a companion diagnostic for TALZENNA® in combination with XTANDI® to identify patients with HRR gene-mutated metastatic castration-resistant prostate cancer. The approval strengthens the use of blood-based comprehensive genomic profiling for therapy selection in advanced prostate cancer.

Industry Experts on North America Liquid Biopsy Market

Rising digitalization in pharmaceutical R&D is driving the North American liquid biopsy market as cloud-based drug-discovery platforms become the foundational infrastructure for integrating advanced technologies across discovery workflows.

Emphasizing the shift towards liquid biopsy, Suketu Shah (Sergio Figueiras Gómez, Innovation Director of Bahia Software), stated, "I believe liquid biopsy holds great potential. Its future evolution relies on establishing well-structured databases, information from diagnostic tools, technicians and the integration of symptoms with the recorder data reports. Creating a comprehensive database with organized data will pave the way for leveraging advanced technologies, such as machine learning and artificial intelligence in this domain, enabling us to extract valuable insights and aiding in treatment decisions and patient care. As a result, the integration of liquid biopsy into routine clinical practice will become more seamless and effective, driving better patient outcomes."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• Chairman, Small Company, US
• Founder and Chief Executive Officer, Small Company, India
• Chief Executive Officer, Small Company, Australia
• Founder, President and Chief Technology Officer, Small Company, US
• Chief Operating Officer and Co-Founder, Small Company, Canada
• Chief Medical Officer, Mid-sized Company, US
• Chief Scientific Officer, Mid-sized Company, US
• Founder and Medical Director, Small Company, Germany
• Founder, Small-sized Company, Sweden
• Innovation Director, Mid-sized Company, Spain
• Director, Mid-sized Company, US
• Former Chief Executive Officer and Co-founder, Small-sized Company, US
• Former Chief Executive Officer, Mid-sized Company, US
• Former Founder, Small-sized Company, US
• Former Marketing Director, Mid-sized Company, Belgium
• Former Strategic Technology Advisor, Small Company, Australia
• Former Sales and Marketing Manager, Small Company, Italy

Market Share Insights

Which Type of Technology Accounts for the Largest Share in the North America Liquid Biopsy Market?

As per North America liquid biopsy market analysis, the next generation sequencing segment holds majority (nearly 50%) of the overall market share in the current year. This can be attributed to its ability to simultaneously analyze multiple genomic alterations with high sensitivity and specificity from a single liquid biopsy sample. Compared to conventional molecular diagnostic techniques, NGS enables comprehensive genomic profiling by detecting single nucleotide variants, insertions / deletions, copy number variations, and gene fusions, making it an essential tool for precision oncology. The widespread adoption of NGS in clinical practice for cancer diagnosis, treatment selection, minimal residual disease (MRD) monitoring, and therapy response assessment has significantly contributed to its market dominance.

Further, the next-generation sequencing (NGS) segment is expected to grow at a significant pace during the forecast period owing to continuous technological advancements that improve sequencing accuracy, reduce turnaround time, and lower testing costs. The expanding clinical applications of NGS, such as early cancer detection, multi-cancer screening, minimal residual disease monitoring, and longitudinal disease surveillance, are expected to drive widespread adoption.

Additionally, it is important to highlight that companies like Illumina continue to introduce next-generation sequencing platforms with higher throughput and improved workflow efficiency, while companies such as Guardant Health and Natera are expanding the clinical utility of NGS-based liquid biopsy assays for early cancer detection and disease monitoring. These developments are expected to drive robust growth in the NGS segment throughout the forecast period.

Which Type of Cancer Accounts for the Largest Share in the North America Liquid Biopsy Market?

Currently, breast cancer holds the largest share of the North America liquid biopsy market owing to its high incidence, extensive use of biomarker-driven treatment strategies, and well-established integration of genomic testing into routine clinical practice. Compared to many other solid tumors, breast cancer management relies heavily on molecular profiling to identify actionable mutations, such as PIK3CA and ESR1, which guide targeted therapy selection in patients with advanced disease. This has significantly increased the clinical adoption of liquid biopsy for mutation detection, treatment monitoring, and identification of acquired therapeutic resistance.

Moreover, the availability of FDA-approved companion diagnostic tests, expanding reimbursement coverage, and strong participation in breast cancer clinical trials have further reinforced the segment's leading market position. For example, Guardant Health and Foundation Medicine offer NGS-based liquid biopsy assays capable of detecting clinically actionable alterations, including PIK3CA and ESR1 mutations, which support personalized treatment decisions in metastatic breast cancer.

The pancreatic cancer segment is expected to grow at a significant pace during the forecast period owing to the increasing need for minimally invasive diagnostic tools for a malignancy that is often detected at an advanced stage and is associated with poor survival outcomes. Tissue biopsy in pancreatic cancer can be technically challenging because of the tumor's anatomical location, making liquid biopsy an attractive alternative for molecular profiling, treatment selection, and disease monitoring. In addition, growing research on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and methylation biomarkers is accelerating the development of liquid biopsy assays for early detection and minimal residual disease (MRD) monitoring.

Scope of North America Liquid Biopsy Market Report